This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies.

filing / Aug 25, 2026 / receipt

or after taxes); operating income; operating income after taxes; pre-tax profit; operating cash flow; sales, annual recurring revenue, or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of working capital levels; economic value added (or an equivalent metric); market share; cash flow; cash flow per share; share price performance; debt reduction

filing / Aug 25, 2026 / receipt

If the Required Company Stockholder Matters are approved, (i) Brigette Roberts, M.D., our current Chief Corporate Affairs Officer, is expected to be appointed as our Chief Executive Officer, (ii) John Militello, our current Head of Finance, is expected to be appointed as our Chief Financial Officer and (iii) Keith Fandrick, our current Head of Technical Operations, is expected to be appointed as our Chief Operating O

filing / Aug 25, 2026 / receipt

The Board has appointed John Militello, CPA, who currently serves as our Head of Finance, as our Chief Financial Officer, which appointment is conditioned upon the effectiveness of the resignation of Mr.

filing / Aug 25, 2026 / receipt

Dirk Thye, M.D., our Chief Executive Officer and Chief Medical Officer;

filing / Aug 25, 2026 / receipt

Charles Ryan, Ph.D., our President;

filing / Aug 25, 2026 / receipt

recession or other economic crisis; (b) credit and capital markets volatility (and access to these markets, including by our suppliers and customers); (c) manufacturing supply disruption due to travel restrictions or other government actions; (d) disruptions in raw material supply, our manufacturing operations, or in our distribution and supply chain; and (e) our ability to conduct planned clinical trials and commerc

filing / Aug 14, 2026 / receipt

Our personnel related costs increased by $3.6 million during the three months ended June 30, 2026 as compared to the three months ended June 30, 2025, mainly as a result of an increase of $2.7 million in allocated stock-based compensation costs and a $0.9 million increase in other personnel related expenses, including costs related to Orphai Acquisition and severance costs related to personnel separation.

filing / Aug 14, 2026 / receipt

Personnel related costs increased by $4.3 million during the six months ended June 30, 2026 as compared to the six months ended June 30, 2025, mainly as a result of an increase of $2.9 million in allocated stock-based compensation costs and a $1.4 million increase in other personnel related expenses, including costs related to Orphai Acquisition and severance costs related to personnel separation.

filing / Aug 14, 2026 / receipt

We anticipate that our research and development expenses will increase from current levels due to the Orphai Acquisition and the increase in headcount as the size of our business and research and development operations grows to support additional research and development activities.

filing / Aug 14, 2026 / receipt

We anticipate that our general and administrative expenses will increase from current levels due to the Orphai Acquisition and the increase in headcount as the size of our business and research and development operations grows to support additional research and development activities.

filing / Aug 14, 2026 / receipt

healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications.

filing / Aug 14, 2026 / receipt